Episode 99: Understanding AMX0035's Potential in Progressive Supranuclear Palsy
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Gunter Hoglinger, MD. [LISTEN TIME: 14 minutes]
Gunter Hoglinger, MD
Episode 99 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 99, "Understanding AMX0035's Potential in Progressive Supranuclear Palsy" features an interview with Gunter Hoglinger, MD, professor of neurology and translational neuroscientist at Ludwig Maximillian's University Munich, provided commentary on a newly initiated phase 3 study assessing AMX0035 (Relyrvio; Amylyx Pharmaceuticals) in patients with progressive supranuclear palsy (PSP). Otherwise known as the ORION trial, Hoglinger discussed what went into trial inclusion, primary end points, and why they believe this therapy, which was approved for patients with amyotrophic lateral sclerosis (ALS) in 2022, could have benefits in PSP.
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- FDA Advisory Committee Downvotes Mesenchymal Stem Cell Approach NurOwn as Potential ALS Therapy
- FDA Approves HoneyNaps’ Artificial Intelligence Sleep Disorder Diagnosis Software
- FDA Approves Cipaglucosidase Alfa and Miglustat as First Two-Component Therapy for Pompe Disease
EPISODE BREAKDOWN
- 1:15 – Underlying mechanisms of progressive supranuclear palsy
- 3:30 – Similarities and differences between ALS and PSP
- 5:00 – Overview of ORION study design
- 7:00 – Neurology News Minute
- 9:15 – Reasons behind specific trial inclusion
- 10:35 – Primary end points of the study
- 12:50 – Significance of a potentially successful trial
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Hoping to listen on your favorite podcast app? See below:
